Research programme: recombinant human lysosomal proteinases - Halozyme Therapeutics

Drug Profile

Research programme: recombinant human lysosomal proteinases - Halozyme Therapeutics

Alternative Names: Metalloproteinase temperature selective recombinant enzyme - Halozyme Therapeutics; MMP1ts; Recombinant enzymes for dermatology - Halozyme Therapeutics

Latest Information Update: 04 Oct 2011

Price : $50

At a glance

  • Originator Halozyme Therapeutics
  • Class Peptide hydrolases
  • Mechanism of Action Protease stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Scars
  • Research Dupuytren's contracture; Peyronie's disease

Most Recent Events

  • 04 Oct 2011 Early research in Peyronie's disease in USA (unspecified route)
  • 04 Oct 2011 Early research in Dupuytren's contracture in USA (unspecified route)
  • 12 Oct 2010 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top